Three‐Year Results of Tapering Tumor Necrosis Factor Inhibitor to Withdrawal Compared to Stable Tumor Necrosis Factor Inhibitor Among Patients With Rheumatoid Arthritis in Sustained Remission: A Multicenter Randomized Trial

医学 逐渐变细 类风湿性关节炎 危险系数 随机对照试验 比例危险模型 内科学 外科 不利影响 置信区间 计算机科学 计算机图形学(图像)
作者
Kaja E Kjørholt,Nina Paulshus Sundlisæter,Anna‐Birgitte Aga,Joseph Sexton,Inge Christoffer Olsen,Åse Stavland Lexberg,Tor Magne Madland,Hallvard Fremstad,Christian A. Høili,Gunnstein Bakland,Cristina Spada,Hilde Haukeland,Inger Marie Jensen Hansen,Ellen Moholt,Karen Holten,Till Uhlig,Tore Kristian Kvien,Daniel H. Solomon,Désirée M F M van der Heijde,Espen Andre Haavardsholm
出处
期刊:Arthritis & rheumatology [Wiley]
卷期号:77 (10): 1327-1336 被引量:6
标识
DOI:10.1002/art.43199
摘要

OBJECTIVE: Tapering of tumor necrosis factor inhibitor (TNFi) treatment in rheumatoid arthritis (RA) remission is debated. We assessed the effect of tapering TNFi to withdrawal versus continued stable TNFi on flare-free survival and joint damage progression over three years. METHODS: ARCTIC REWIND was a multicenter open-label, noninferiority trial that included patients with RA in remission for ≥12 months taking stable TNFi therapy. Patients were randomized 1:1 to taper TNFi to withdrawal or continue stable treatment. The primary end points of the current study were flare-free survival and radiographic progression over three years. Flare-free survival was analyzed by Kaplan-Meier methods, flare rates were analyzed by Cox regression, and radiographic progression was analyzed by logistic mixed-effects models. RESULTS: Of 99 randomized patients, 92 received the allocated therapy, and 80 completed the three-year follow-up. The mean baseline Disease Activity Score based on the 44 joint count was 0.8, and conventional synthetic disease-modifying antirheumatic drug comedication was used by 90% of patients. After three years, 25% (95% confidence interval [CI] 13%-38%) remained flare free in the tapering TNFi group, compared to 85% (95% CI 70%-93%) in the stable group, and the corresponding hazard ratio for flare was 9.4 (95% CI 3.9-22.8, P < 0.0001). In the tapering group, 6 of 41 (15%) experienced radiographic progression, compared with 3 of 38 (8%) in the stable group (risk difference 6.7%, 95% CI -7.1% to 20.5%, P = 0.3). Adverse events occurred in 81% of the patients in the tapering group and 89% of the patients in the stable group. CONCLUSION: In contrast to those receiving stable TNFi treatment, a minority of patients with RA in remission tapering TNFi to withdrawal remained flare free over three years. There was no statistically significant difference in radiographic progression between the groups.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
lilili的应助被木夫贝采纳,获得10
1秒前
充电宝的应助被kiko采纳,获得10
1秒前
北林发布了新的文献求助10
1秒前
2秒前
大个的应助被科研通管家采纳,获得10
2秒前
打打的应助被科研通管家采纳,获得10
2秒前
3秒前
FashionBoy的应助被科研通管家采纳,获得10
3秒前
wanci的应助被科研通管家采纳,获得10
3秒前
cdercder的应助被科研通管家采纳,获得10
3秒前
完美世界的应助被科研通管家采纳,获得10
3秒前
3秒前
852的应助被科研通管家采纳,获得10
3秒前
3秒前
20的应助被科研通管家采纳,获得10
3秒前
成就含海完成签到 ,获得积分10
3秒前
852的应助被科研通管家采纳,获得10
3秒前
Youdge的应助被饮冰采纳,获得30
4秒前
4秒前
Lucas的应助被科研通管家采纳,获得10
4秒前
Hello的应助被科研通管家采纳,获得10
4秒前
无花果的应助被科研通管家采纳,获得10
4秒前
圣晟胜完成签到,获得积分10
4秒前
上官若男的应助被科研通管家采纳,获得10
4秒前
4秒前
小蘑菇的应助被科研通管家采纳,获得10
4秒前
蓝天的应助被科研通管家采纳,获得10
4秒前
风格的应助被科研通管家采纳,获得30
5秒前
5秒前
傲娇冰枫完成签到,获得积分10
5秒前
传奇3的应助被科研通管家采纳,获得10
5秒前
5秒前
李健的应助被科研通管家采纳,获得50
5秒前
7秒前
火星上的煎蛋的应助被Camellia采纳,获得10
7秒前
taotao完成签到,获得积分10
7秒前
傲娇冰枫发布了新的文献求助10
9秒前
鉴心完成签到 ,获得积分10
9秒前
renn发布了新的文献求助10
9秒前
9秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183894
求助须知:如何正确求助?哪些是违规求助? 9573067
关于积分的说明 21829226
捐赠科研通 7780983
什么是DOI,文献DOI怎么找? 3434150
关于科研通互助平台的介绍 2558315
邀请新用户注册赠送积分活动 2480648